DOVONEX - CRM 50MCG/GM 50 MCG — DIN 02150956
CALCIPOTRIOL : 50 MCG · LEO PHARMA INC · CREAM · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is DOVONEX - CRM 50MCG/GM?
DOVONEX - CRM 50MCG/GM 50 MCG contains CALCIPOTRIOL : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02150956, held by LEO PHARMA INC, supplied as CREAM for TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 11-Mar-2016. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is DOVONEX - CRM 50MCG/GM used for?
DOVONEX (calcipotriol) cream and ointment is indicated for the topical treatment of psoriasis and for combination use with a moderate to very potent topical corticosteroid, cyclosporin A or acitretin. DOVONEX scalp solution is indicated for the topical treatment of scalp psoriasis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Calcipotriol cost around the world?
Calcipotriol is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Brazil publishes a preco fabrica (ex-factory ceiling). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 6 | 12 | AUD███.██ |
| Spain | PVP con IVA (public price) | 6 | 6 | EUR███.██ |
| Luxembourg | reimbursement | 6 | 6 | EUR███.██ |
| Austria | KVP (Kassenverkaufspreis) | 3 | 4 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 3 | 3 | CZK███.██ |
| Greece | producer price (ex-factory) | 3 | 3 | EUR███.██ |
| Hungary | producer price (ex-factory) | 3 | 3 | HUF███.██ |
| Morocco | PPV (public price) | 1 | 3 | MAD███.██ |
| South Africa | single exit price | 2 | 3 | ZAR███.██ |
| Brazil | preco fabrica (ex-factory ceiling) | 1 | 1 | BRL███.██ |
44 pack listings across 34 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Calcipotriol pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Calcipotriol in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Calcipotriol — 3 DINs, of which 1 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| LEO PHARMA INC | 3 | 1 | DOVONEX, DOVONEX - CRM 50MCG/GM, DOVONEX SOLUTION - TOP 50MCG/ML | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 50 MCG |
|---|---|
| Dosage form | CREAM |
| Route | TOPICAL |
| Pack configuration (monograph) | Cream and ointment: 15g, 60g and 120g lacquered aluminium tubes and 240g laminate tubes (equipped with an aluminium membrane). Scalp solution: 30 mL, 60 mL, and 120 mL polyethylene bottles. |
| Storage | Cream and Ointment: Store at room temperature (15-25 °C). For easy application: do not refrigerate (this is to prevent pulling of delicate skin). Scalp Solution: Store below 25 °C. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Calcipotriol |
|---|---|
| ATC code | D05AX02 |
| AHFS class | 84:92.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02150956 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2150956 |
| Brand name | DOVONEX - CRM 50MCG/GM |
| Generic / active ingredient | CALCIPOTRIOL : 50 MCG |
| Market authorization holder | LEO PHARMA INC |
| Health Canada schedule | Prescription |
| ATC code | D05AX02 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D05AX |
| Current status | CANCELLED POST MARKET |
| Status date | 11-Mar-2016 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 3 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOVONEX | 50 MCG | OINTMENT | LEO PHARMA INC | MARKETED | 01976133 |
| DOVONEX SOLUTION - TOP 50MCG/ML | 50 MCG | SOLUTION | LEO PHARMA INC | CANCELLED POST MARKET | 02194341 |
2 · Same class — other molecules in ATC D05AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Calcipotriol, Combinations | DOVOBET GEL · DOVOBET OINTMENT · ENSTILAR · TARO-CALCIPOTRIOL / BETAMETHASONE GEL | 4 | 4 | Yes |
| Roflumilast | ZORYVE | 3 | 3 | Yes |
| Tazarotene | ARAZLO · DUOBRII · TAZORAC | 6 | 2 | Yes |
| Calcipotriol | DOVONEX · DOVONEX - CRM 50MCG/GM · DOVONEX SOLUTION - TOP 50MCG/ML | 3 | 1 | Yes |
| Tapinarof | NDUVRA | 1 | 1 | Yes |
| Calcitriol | SILKIS | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D05AA | Tars | 100 | 4 |
| D05AC | Dithranol | 8 | 0 |
| D05AD | Methoxalen, Topical | 2 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DOVONEX - CRM 50MCG/GM called?
The same molecule, Calcipotriol, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| DAIVONEX | Latin | Brazil, Morocco |
| Enstilar | Latin | Australia, Czechia |
| Daivobet | Latin | Australia |
| Dovonex | Latin | South Africa |
| Klarvanta | Latin | Australia |
| TALIZON | Latin | Czechia |
| WYNZORA | Latin | Czechia |
| Xamiol Gel | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.